Pfizer Venture Investments — Full Portfolio

Bolt Biotherapeutics develops cancer immunotherapies that use the innate immune system to help the body recognize and eliminate tumor cells.

Co-investorsRA CapitalVivo CapitalNan Fung Life SciencesNovo HoldingsPivotal Life SciencesSofinnova Ventures

Enliven Therapeutics is a biopharmaceutical company developing small molecule precision therapeutics, including ELVN-001, a selective active site inhibitor of BCR::ABL1 for patients with chronic myeloid leukemia (CML).

BiotechHealthtech

Co-investors5AM VenturesOrbiMedRoche Venture Fund

Ginkgo Bioworks builds autonomous labs and offers cell-programming and bioengineering services for the biopharma, agriculture, and industrial biotech markets.

AgTechAI & Machine LearningBiotechDeep TechHealthtechBoston, US

Jason Kelly(Founder)inAustin Che(Founder)inTom Knight(Founder)inBarry Canton(Founder)inReshma Shetty(Founder)in

BoardReshma Sohoni

Co-investors11.2 CapitalB3 HoldingCannage CapitalCool Climate CollectiveDCVC (Data Collective)Designer Fund+15 more

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

Nello Mainolfi(Founder)in

Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersNextech InvestSanofi Ventures+2 more

Co-investorsBay City CapitalCanaan Partners

Novocure is a global oncology company developing Tumor Treating Fields therapies, including its Optune Pax device, to treat aggressive cancers such as locally advanced pancreatic cancer.

BiotechHealthtechMedical Devices

Co-investorsWindham Capital Partners

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

Bharatt Chowrira(Executive Officer)Michael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)Paul Miller(Executive Officer)Aoife Brennan(Executive Officer)Todd Shegog(Executive Officer)

Co-investorsAtlas VentureNew Enterprise Associates (NEA)NSG VenturesSofinnova VenturesSolasta VenturesOrbiMed

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Timothy Mayer(Executive Officer)Michael Richman(Executive Officer, Director)Elaine V. Jones(Director)Udayan Guha(Executive Officer)Anne Borgman(Director)Steven P. Cobourn(Executive Officer)

Co-investorsCanaan PartnersLAVLilly Asia VenturesQuan CapitalSofinnova VenturesTaiho Ventures, LLC+1 more

RefleXion Medical develops SCINTIX autonomous radiotherapy, an external beam theranostic oncology platform that uses biological signals from radiopharmaceutical-labeled cancer cells to deliver real-time, motion-managed radiation to lung and bone tumors from primary or metastatic disease.

BiotechHealthtechMedical DevicesHayward, US

Board seatRana Al-Hallaq· per SEC Form D

Co-investorsAscension VenturesCatalio Capital Management, LPSofinnova PartnersSonder CapitalSonder Futures

AMRA Medical provides MRI-based body composition analytics that generate fat and muscle biomarkers for clinical trials and clinical decision-making.

AI & Machine LearningHealthtechMedical Devices

Co-investorsHealthCap

Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.

BiotechBasel, CH

Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in

Co-investorsNovartis Venture FundPontifax Venture Capital

Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.

ConsumerGamingBaku, AZ

Co-investorsAtlas VentureMission BiocapitalPfizer Ventures

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

Michael Gilman(Executive Officer, Director)Mark DeLong(CEO)David Neafus(Executive Officer)Russell C. Petter(Executive Officer)

BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in

Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesNextech InvestOUP (Osage University Partners)venBio Partners+1 more

Artios develops DNA Damage Response (DDR)-based therapeutics for hard-to-treat solid tumors, including small-molecule inhibitors targeting ATR (alnodesertib) and DNA polymerase theta (ART6043).

BiotechHealthtech

Co-investorsAndera PartnersM VenturesNovartis Venture FundRA CapitalSofinnova PartnersSV Health Investors

Co-investorsSV Health Investors

Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.

BiotechDeep TechMedical DevicesSan Diego, US

Kevin Finney(Chairman, President and CEO)John Borkholder(Executive Officer)

BoardKristina Burow(Director)inThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)

Co-investorsARCH Venture PartnersCanaan PartnersMonograph Capital PartnersSamsara BioCapitalNewpath Partners

Co-investorsBioAdvanceOUP (Osage University Partners)

Developing bispecific antibodies for precision autoimmune applications

Co-investorsPathway Bioventures

BioNTech is a biotechnology company developing immunotherapies that use the body's immune system, combining multiple therapeutic modalities and biological targets to treat cancer, infectious diseases, and other serious conditions.

BiotechHealthtech

Co-investorsManta Ray VenturesMIG Capital AGOnsight Ventures

BiotechSouth San Francisco, US

Wendye Robbins(Executive Officer, Director)

BoardLuke Evnin(Director)inCameron Wheeler(Director)Peter van Vlasselaer(Director)Elaine Jones(Director)William Slattery(Director)

Co-investorsBay City CapitalOUP (Osage University Partners)+ND CapitalMPM BioImpact

BiotechSan Diego, US

Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)Ramin Farzaneh-Far(Executive Officer)Justin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)

Co-investorsRA Capital

Molecular diagnostics company offering clinical PCR systems using automation and microfluidics; acquired by QIAGEN in September 2020.

BiotechHealthtechAlbuquerque, US

Thomas Duensing(Executive Officer)Dennis Hynson(Executive Officer)Janette Phi(Executive Officer)R. Terry Dunlay(Executive Officer, Director)Sundaresh Brahmasandra(Executive Officer)Jeffrey Williams(Executive Officer, Director)

Co-investors1315 Capital1s1 EnergyABAN.VCAdBio partnersAdjuvoAgile Capital+118 more

Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.

AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US

Max Mumbach(Founding Scientist, Target Discovery)Jeffrey Verboon(Founding Scientist, Computational Biology)Ansu Satpathy(Founder)Kevin Parker(Chief Executive Officer)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)

Co-investors8VCAndreessen HorowitzArtis VenturesGlobal BioAccess FundHAWKTAILWing+6 more

Co-investorsFrazier Life Sciences

BiotechPittsburgh, US

Joshua M. Tarnoff(Executive Officer, Director)Diane Jorkasky(Chief Medical Officer)Federica O'Brien(Chief Financial Officer)Hironori Hozoji(Director)

BoardI. Wistar Morris(Director)Kenji Harada(Director)

Co-investorsAndera PartnersNew Enterprise Associates (NEA)

Co-investorsDolby Family Ventures

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in

BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in

Co-investorsMPM BioImpactPfizer VenturesPolaris PartnersTaiho Ventures, LLC

Curve Therapeutics is a drug discovery company that uses a proprietary gene-encoded, high-throughput intracellular platform to screen libraries of cyclic peptides inside live mammalian cells.

AI & Machine LearningBiotechDeep Tech

Co-investorsEpidarex CapitalColumbus Venture Partners

CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.

BiotechHealthtech

Sean A. McCarthy(Chief Executive Officer and Chairman)Marcia P. Belvin(SVP, Chief Scientific Officer)Dawn Benson(SVP, Quality and Product Manufacturing)Wayne Chu(Chief Medical Officer)Rachael Lester(SVP, Chief Business Officer)Chris Ogden(Chief Financial Officer)

Co-investorsCanaan PartnersLongitude CapitalOrbiMed

DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.

BiotechHealthtechCambridge, US

Nenad Grmusa(Chief Executive Officer)John McCabe(Chief Financial and Operating Officer)

Co-investorsAlta PartnersAstellas Venture Management LLCDC Investment PartnersLongwood FundUTokyo Innovation Platform Co. Ltd.Insight Partners+1 more

Acquired by Fluidigm/Standard BioTools.

Co-investorsFACIT (Fight Against Cancer Innovation Trust)

eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.

BiotechSolana Beach, US

Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)

BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)

Co-investorsAstellas Venture Management LLCMission Bay CapitalMission BiocapitalOUP (Osage University Partners)US Venture PartnersSofinnova Ventures

BiotechSanta Clara, US

Jeffrey Glenn(Director)David Cory(Executive Officer, Director)

BoardNina Kjellson(Director)inEd Engleman(Director)

Co-investorsCanaan PartnersVivo Capital

Co-investorsM VenturesRA Capital

Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.

BiotechDeep TechSan Diego, US

Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)

Co-investorsFrazier Life SciencesLightspeed Venture PartnersSamsara BioCapitalAvalon BioVenturesOrbiMed

Medtronic designs and develops medical technology for treating complex diseases.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Co-investors8VCCWRU Technology VenturesElevate VenturesMenlo VenturesOak Investment PartnersQuesta Capital+5 more

Flare Therapeutics is a drug discovery company developing small molecule therapies that target transcription factors to restore transcriptional control disrupted by cancer.

BiotechHealthtech

Co-investorsNextech InvestShangBay Capital LLCAgent Capital

FoRx Therapeutics is a clinical-stage biotechnology company developing small-molecule drugs that target DNA replication stress in treatment-resistant cancers.

BiotechDeep TechHealthtechBasel, CH

Co-investorsNovartis Venture FundM Ventures

Genetic research and cancer detection; IPO and acquired by Exact Sciences

Co-investorsKleiner PerkinsVedanta Capital

Genomic Health develops diagnostic tests and related services and runs health-equity initiatives aimed at improving access, awareness, and outcomes for patients and communities, including uninsured and underinsured populations.

BiotechDigital HealthHealthtechMedical Devices

Steve Shak(Founder)inKevin Conroy(CEO)

Co-investorsKleiner Perkins

Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.

BiotechDigital HealthHealthtechMedical DevicesOxford, GB

Peter Joyce(Co-founder)Tom McCarthy(Co-founder)

Co-investorsAndera PartnersCanaan PartnersOxford Science Enterprises

Developer of antibody therapeutics targeting butyrophilin checkpoint molecules for cancer; acquired by Ipsen in 2025.

Co-investorsPureos Bioventures

Immunocodex develops tolerogenic mRNA vaccines that reprogram immune cells and rebalance the immune system to treat autoimmune diseases.

BiotechLongevity

Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.

BiotechHealthtechMedical Devices

Co-investorsBioMedPartnersLightspeed Venture PartnersMission BiocapitalPfizer Venturesredalpine

BiotechPhiladelphia, US

Philip R. Johnson, M.D.(Executive Officer, Director)Dora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)

BoardTomas Kiselak(Director)

Co-investorsOUP (Osage University Partners)

Clinical-stage biotech using its RAPID chemoproteomics platform to drug challenging targets; acquired by Otsuka in 2024.

Boston, US

Co-investorsAvalon BioVenturesBain Capital Life SciencesRA Capital

BiotechBoston, US

Frank G. Haluska(Executive Officer, Director)

BoardOmar Khalil(Director)Nicholas Saccomano(Director)Barbara Sosnowski(Director)Andrew Phillips(Director)Denis Patrick(Director)

BiotechNew York, US

David Pompliano(Executive Officer)David McElligott(Executive Officer, Promoter)

BoardDavid Schubert(Executive Officer, Promoter)Joel Marcus(Director)Lindsay Rayle(Executive Officer, Promoter)Barbara Dalton(Director)

Co-investorsDigitalis Ventures

BiotechNew York, US

M. Johnston Erwin(Director)Ian Howes(Executive Officer)Thong Le(Executive Officer, Director)David Schubert(Executive Officer)Kendall Mohler(Executive Officer)

BoardBarbara Dalton(Director)

Mediartx develops novel therapies for patients with fibrotic diseases.

BiotechMedical DevicesBoston, US

Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)Brian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)

Co-investorsLongwood FundMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.ShangBay Capital LLCSofinnova Partners+2 more

A biopharmaceutical company developing targeted oncology medicines, with a focus on treatments for patients of all ages including children with cancers such as pediatric low-grade glioma (pLGG).

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

MICHAEL J. KAUFMAN(Executive Officer)DONALD BERGSTROM(Executive Officer)ANNA PROTOPAPAS(Executive Officer, Director)DAVID MOTT(Director)TIMOTHY LOWINGER(Executive Officer)EVA JACK(Executive Officer)

Co-investorsBain Capital Life SciencesF-Prime Capital PartnersLightstone VenturesNew Enterprise Associates (NEA)Nextech InvestRho Ventures

Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.

BiotechMedical DevicesUtrecht, NL

Ton Logtenberg(Executive Officer, Director)Mark Throsby(Executive Officer)Hui Liu(Executive Officer)John Crowley(Executive Officer)L. Andres Sirulnik(Executive Officer)Lex Bakker(Executive Officer)

Co-investorsAvoro Capital AdvisorsRA CapitalSofinnova Ventures

Co-investorsPontifax Venture Capital

BiotechKingston, US

Robert B. Nelson(Executive Officer, Director)Frank S. Menniti(Executive Officer, Director)Stevin Zorn(Executive Officer, Director)Isaac Stoner(CEO)

BoardRichard G. Horan(Director)Reetika Bhardwaj(Director)

Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.

BiotechHealthtech

Co-investorsRoche Venture FundSofinnova PartnersSR One Capital Management

BiotechNew York, US

Nicholas Hertz(Director)Doug Crawford(Director)Daniel de Roulet, Jr.(Executive Officer, Director)

BoardJohannes Fruehauf(Director)

Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.

BiotechHealthtechLeuven, BE

Federico Grossi(Clinical Advisor & Acting CMO)

Co-investorsDroia VenturesPfizer VenturesVIB

Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.

BiotechMedical Devices

Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)

Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Sofinnova PartnersPfizer Ventures

NexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses.

BiotechMedical DevicesGaithersburg, US

Jonathan Schneck(Director)Alain Cappeluti(Executive Officer, Director)Kenneth Carter(Executive Officer, Director)

BoardJanis Naeve(Director)James Barrett(Director)

Co-investorsRapha Capital Management, LLC

Harnesses cutting-edge technologies to design exquisitely selective small molecule therapeutics.

Co-investorsAccess BiotechnologyBain Capital Life SciencesLightstone VenturesRA CapitalSV Health Investors

Normunity is a cancer immunotherapy company applying an immunology-based approach to identify novel anti-cancer targets at the interface of the immune system and cancer, using proprietary platforms and human cells and tissues.

AI & Machine LearningBiotechHealthtech

Rachel Humphrey(Founding Chief Executive Officer)Lieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)William LaRochelle(Chief Scientific Officer)Stacy M. Plum(Chief Technology Officer)

Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut Innovations+1 more

Quince Therapeutics is a clinical-stage biopharmaceutical company developing eDSP, an investigational therapy studied in a Phase 3 clinical trial (NEAT) for patients with Ataxia-Telangiectasia (A-T).

BiotechHealthtechWest Lafayette, US

Philip S. Low, Ph.D.(Executive Officer, Director)David Lamond(Director)Daniel Hasler(Director)Dirk Thye, M.D.(Executive Officer, Director)William J. Rutter(Director)Alex Andrianopoulos(Director)

Co-investorsBreakout VenturesElevate Ventures

Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.

AI & Machine LearningBiotechDeep Tech

Co-investorsM VenturesOxford Science EnterprisesBritish Patient CapitalJJDCPfizer Ventures

Keenova Therapeutics is a specialty pharmaceutical company developing treatments for rare, stigmatized, or unaddressed conditions across therapeutic areas including immunology, urology, hepatology, ophthalmology, orthopedics, and critical care.

BiotechHealthtechMedical Devices

Co-investorsARCH Venture PartnersCross Creek AdvisorsSignet Healthcare PartnersSofinnova Ventures

BiotechCambridge, US

Robert Prentiss(Executive Officer)Ronald C. Renaud, Jr.(Executive Officer, Director)Thomas McCauley(Executive Officer)

BoardBrian Gallagher(Director)Jean- Francois Formela(Director)inJoshua Resnick(Director)

Co-investorsAtlas Venture

Co-investorsOUP (Osage University Partners)Sanofi Ventures

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechMedical Devices

Dr. Daniel J. Siegwart

Co-investorsAju IB Invesment CorporationEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedSanofi Ventures+3 more

Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.

Advanced ManufacturingBiotechEnterprise SoftwareBlue Ash, US

William S. Marth(Chief Executive Officer)

BoardRobert Nelsen

Co-investors8VCARCH Venture PartnersCatalio Capital Management, LPGV (Google Ventures)Koch Disruptive TechnologiesLux Capital+4 more

Rhythm Pharmaceuticals is a biopharmaceutical company that develops precision medicines and treatment options for patients with rare neuroendocrine diseases, including hyperphagia and obesity.

BiotechHealthtechBoston, US

Keith Gottesdiener(Executive Officer, Director)Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)

BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)inNeil Exter(Director)inTodd Foley(Director)

Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)OrbiMedThird Rock Ventures

Saama provides AI-based data analytics solutions and services for the life sciences industry, with a focus on accelerating clinical trials.

AI & Machine LearningData & InfrastructureDigital HealthHealthtechSaaSCampbell, US

Suresh Katta(Executive Officer, Director)Simon Ho(Executive Officer)

BoardMarc McMorris(Director)inKen Coleman(Director)Dan Fishback(Director)William Binch(Director)

Co-investorsCarrick Capital PartnersMcKesson Ventures

Co-investorsLifeforce CapitalDigitalis Ventures

Simcha Therapeutics is a clinical-stage biotech company developing protein therapeutics, with pipeline programs focused on cytokines and immunotherapies for oncology.

BiotechHealthtechNew Haven, US

Aaron Ring(Executive Officer, Director)Beatrice McQueen(Chief Operating Officer)Sanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)Hirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)

Co-investorsConnecticut InnovationsAxial VCSR One Capital Management

HealthtechStamford, US

Daniel S. Lynch(Executive Officer, Director)Saqib Islam(Executive Officer, Director)Michael Greco(Executive Officer)

BoardStephen Squinto(Director)inDeval Patrick(Director)Carl L Gordon(Director)in

Co-investorsBain Capital Life SciencesOrbiMed

QIAGEN provides sample preparation and molecular testing technologies, including automated DNA/RNA extraction, digital PCR, and syndromic testing systems.

BiotechHealthtechMedical Devices

Co-investorsHarmonic Growth PartnersYsios Capital

STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.

BiotechHealthtechMedical Devices

Co-investorsFast Track InitiativeSeroba Life SciencesTaiho Ventures, LLCUTokyo Innovation Platform Co. Ltd.Cambridge Innovation CapitalM Ventures

Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies.

AI & Machine LearningBiotechDigital HealthMedical DevicesAnn Arbor, US

Daniel Rhodes(Executive Officer, Director)Matthew Martin(Executive Officer)Jeffrey Williams(Executive Officer, Director)

BoardChristopher O'Donnell(Director)inDavid Rubin(Director)inJames Pavlik(Director)in

Co-investorsArboretum VenturesDeerfield Management CompanyMerck Global Health Innovation FundPfizer Ventures

Biotech decoding human tissue immune biology to create therapeutics.

Co-investorsAvego BioScience CapitalSV Health Investors

Platform company targeting selective clearance of intracellular protein aggregates in neurodegenerative disease.

Co-investorsCambridge Innovation CapitalM VenturesStart Codon

Co-investorsCTI Life Sciences Fund L.P.Sofinnova Partners

TrimTech Therapeutics develops a portfolio of targeted protein degraders, called TRIMTACs and TRIMGLUEs, that selectively remove toxic protein aggregates.

BiotechDeep Tech

Co-investorsCambridge Innovation Capital

4D Molecular Therapeutics develops genetic medicines using a directed-evolution vector platform to create customized AAV vectors optimized for specific diseases.

BiotechHealthtech

Co-investorsAmzak HealthBerkeley CatalystBOLD Longevity

Ablexis develops the AlivaMab Mouse, a transgenic platform used to discover and develop antibody and antibody-derivative drug candidates.

BiotechDeep Tech

Co-investorsCalifornia Technology Ventures

Adapsyn applies artificial intelligence and computational omics methods to natural product drug discovery, using machine learning for biological activity prediction and de novo drug design.

AI & Machine LearningBiotechDeep Tech

Co-investorsGenesys Capital

Aquinnah Pharmaceuticals develops oral small-molecule therapeutics targeting pathologic biomolecular condensates, such as stress granules formed by RNA-binding proteins, to slow neurodegenerative diseases including ALS and Alzheimer's disease.

BiotechHealthtechLongevity

Benjamin Wolozin(CSO & Co-founder)

Co-investorsTCG CrossoverM Ventures

Autifony Therapeutics develops ion channel-based medicines, focused on Kv3 potassium channel modulators, to treat rare central nervous system disorders such as Fragile X syndrome and rare epilepsy syndromes.

BiotechHealthtech

Co-investorsTectonic Ventures

BD (Becton, Dickinson and Company) develops medical technology and solutions used across healthcare settings, including devices and products supporting emergency medications and patient care.

HealthtechMedical Devices

BioAtla develops antibody-based cancer therapeutics using its Conditionally Active Biologics (CAB) platform, which produces antibodies and other biologics that can be activated or inactivated under specific physiological conditions to improve safety and efficacy.

BiotechHealthtech

BioNTech develops immunotherapies that use the body's immune system to treat cancer, infectious diseases, and other serious illnesses.

BiotechHealthtech

Co-investorsHM Venture PartnersSalvia

BlueLight Therapeutics uses a proprietary platform based on Second Harmonic Generation (SHG) to measure real-time structural changes of biomolecules, applying this structure-driven approach to discover and develop therapeutic molecules for difficult-to-drug, high-value targets.

BiotechDeep TechSouth San Francisco, US

Co-investors5AM VenturesPfizer Ventures

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

BiotechHealthtechMedical Devices

Co-investorsSofinnova VenturesVida Ventures

Enara Bio is a biopharmaceutical company developing cancer immunotherapies for solid tumors, using its EDAPT platform to discover novel tumor-specific "Dark Antigens" from genomic dark matter and its EnTiCE platform to build bispecific T-cell engagers.

Biotech

Co-investorsM Ventures

Enodia Tx develops small-molecule therapies that selectively degrade disease-driving proteins at the point of synthesis by targeting the Sec61 translocon, aiming to eliminate pathogenic proteins before they mature.

BiotechDeep Tech

EvolveImmune develops trispecific T cell engagers with integrated CD2 costimulation through its EVOLVE platform to address cancer cell resistance to immunotherapies.

BiotechHealthtech

Co-investorsSolasta Ventures

G-CON manufactures prefabricated and modular cleanroom solutions, including its POD Cleanrooms, that can be installed within about six months for pharmaceutical and biotech manufacturing facilities.

Advanced ManufacturingBiotechConstruction Tech

Co-investorsWP Global Partners

Co-investorsLAVLilly Asia Ventures

ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.

BiotechHealthtech

Co-investorsAndera PartnersKurma PartnersAgent Capital

Co-investorsBreakout VenturesTaiho Ventures, LLC

Co-investorsDC Investment PartnersLongwood FundQuan CapitalAgent Capital

Jnana Therapeutics operates a chemoproteomics-based drug discovery platform called RAPID to identify small molecule medicines targeting protein binding sites across multiple target classes.

BiotechDeep Tech

Co-investorsAvalon BioVentures

Kestrel Therapeutics is a clinical-stage biotechnology company developing small molecule inhibitors that target KRAS mutations across tumor types for patients with intractable cancers.

BiotechHealthtech

Co-investorsKeiretsu ForumTSVC

Levicept develops a therapeutic aimed at treating chronic pain caused by osteoarthritis, intended as an alternative to prolonged opioid use and NSAIDs.

BiotechHealthtech

MindImmune develops therapeutics targeting the immune drivers of neurodegenerative diseases such as Alzheimer's, focusing on immune cells that respond to amyloid plaques before they enter the brain.

BiotechHealthtech

Co-investorsSlater Technology FundDolby Family Ventures

Co-investorsMission Bay Capital

Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome.

BiotechHealthtechLeuven, BE

Federico Grossi(Clinical Advisor & Acting CMO)

Co-investorsDroia VenturesPfizer VenturesVIB

Co-investorsEcoR1 Capital

Nimbus Therapeutics designs and develops small molecule medicines using computational drug design and translational medicine.

BiotechDeep Tech

Co-investorsAtlas VentureLightstone Ventures

Palleon Pharma develops medicines for autoimmune diseases and cancer based on glycobiology.

Biotech

PrescriberPoint provides prescribing tools for healthcare providers, offering FDA medication label data, drug interaction information, patient education materials, and prior authorization assistance in one platform.

Digital HealthHealthtechSaaS

Pyxis Oncology develops clinical-stage cancer therapeutics, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies, aimed at difficult-to-treat cancers.

BiotechHealthtech

Co-investorsLongwood FundAgent Capital

RefleXion Medical develops SCINTIX autonomous radiotherapy, an external beam theranostic oncology platform that detects biological signals emitted by tumors (via absorbed radiopharmaceuticals) to deliver targeted radiation to moving lung or bone tumors from primary or metastatic cancer.

BiotechHealthtechMedical DevicesHayward, US

SpringWorks is a biopharmaceutical company developing targeted oncology and rare disease therapies, including its gamma secretase inhibitor nirogacestat being evaluated in BCMA combination regimens for multiple myeloma.

BiotechHealthtech

Co-investorsFrazier Life Sciences

TRexBio develops Treg-focused biologic therapeutics for autoimmune and inflammatory diseases, using its Deep Biology Platform to analyze regulatory T cell behavior in human tissues and identify therapeutic targets.

AI & Machine LearningBiotechHealthtech

Co-investorsAvego BioScience CapitalDelos CapitalAgent Capital

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

Patrick Trojer(President & CEO, Co-founder)

Co-investorsAtlas VentureAscenta CapitalBessemer Venture PartnersLightspeed Venture PartnersPfizer VenturesRA Capital

Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases.

BiotechHealthtech

Vibrant Therapeutics develops multispecific antibody-based prodrugs with conditional activation and targeted delivery for patients with oncological, autoimmune, and neurological diseases.

AI & Machine LearningBiotechHealthtech

WEX Health provides benefits administration technology and services, including enrollment, ACA and COBRA compliance, and reimbursement and savings accounts such as HSAs, FSAs, and HRAs.

FintechHR TechSaaS

VitaDAO is a decentralized autonomous organization that funds and coordinates longevity and aging research using AI agents, decentralized governance, and on-chain funding mechanisms such as IP-NFTs.

BiotechCrypto & Web3Longevity

Co-investorsCollab+CurrencySora VenturesTioga Capital Partners

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.

BiotechHealthtechParis, FR

Co-investorsHealthCapKurma PartnersNovartis Venture FundRoche Venture FundYsios CapitalColumbus Venture Partners+1 more

HealthtechBoston, US

N. Anthony Coles(Executive Officer, Director)Richard Peters(Executive Officer, Director)Paulash Mohsen(Executive Officer)Brigitte Robertson(Executive Officer)Richard A. Heyman(Director)Jeffery W. Kelly(Director)